REGENXBIO, Inc. (RGNX)
7.65
-0.38
(-4.73%)
USD |
NASDAQ |
Nov 13, 16:00
7.65
0.00 (0.00%)
After-Hours: 19:59
REGENXBIO Net Income (Quarterly) : -40.74M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -40.74M |
| June 30, 2026 | 22.71M |
| March 31, 2026 | -90.05M |
| December 31, 2025 | -67.15M |
| September 30, 2025 | -61.94M |
| June 30, 2025 | -70.87M |
| March 31, 2025 | 6.083M |
| December 31, 2024 | -51.19M |
| September 30, 2024 | -59.60M |
| June 30, 2024 | -52.99M |
| March 31, 2024 | -63.33M |
| December 31, 2023 | -62.89M |
| September 30, 2023 | -61.87M |
| June 30, 2023 | -72.06M |
| March 31, 2023 | -66.68M |
| December 31, 2022 | -59.94M |
| September 30, 2022 | -75.48M |
| June 30, 2022 | -68.18M |
| March 31, 2022 | -76.72M |
| December 31, 2021 | 294.02M |
| September 30, 2021 | -58.40M |
| June 30, 2021 | -57.64M |
| March 31, 2021 | -50.14M |
| December 31, 2020 | -46.24M |
| Date | Value |
|---|---|
| September 30, 2020 | 8.791M |
| June 30, 2020 | -33.76M |
| March 31, 2020 | -40.04M |
| December 31, 2019 | -26.46M |
| September 30, 2019 | -34.58M |
| June 30, 2019 | -1.457M |
| March 31, 2019 | -32.23M |
| December 31, 2018 | 4.306M |
| September 30, 2018 | -19.20M |
| June 30, 2018 | 10.59M |
| March 31, 2018 | 104.24M |
| December 31, 2017 | -16.00M |
| September 30, 2017 | -20.71M |
| June 30, 2017 | -14.47M |
| March 31, 2017 | -21.99M |
| December 31, 2016 | -19.61M |
| September 30, 2016 | -18.15M |
| June 30, 2016 | -14.44M |
| March 31, 2016 | -10.77M |
| December 31, 2015 | -5.178M |
| September 30, 2015 | -7.332M |
| June 30, 2015 | -6.29M |
| March 31, 2015 | -4.011M |
| March 31, 2014 | 0.795M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 4.207B |
| Anika Therapeutics, Inc. | -0.311M |
| United Therapeutics Corp. | 258.60M |
| Biomea Fusion, Inc. | -6.183M |
| ACADIA Pharmaceuticals, Inc. | 53.52M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 9.162M |
| Total Expenses (Quarterly) | 49.90M |
| EPS Diluted (Quarterly) | -0.6242 |
| Enterprise Value | 531.96M |
| Gross Profit Margin (Quarterly) | 49.18% |
| Profit Margin (Quarterly) | -444.6% |
| Earnings Yield | -41.97% |
| Normalized Earnings Yield | -47.31 |